Lewis Titterton, Jr. Acquires 10,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis Titterton, Jr. purchased 10,000 shares of the stock in a transaction dated Thursday, September 10th. The shares were bought at an average price of $2.73 per share, with a total value of $27,300.00. Following the completion of the acquisition, the director directly owned 996,967 shares of the company’s stock, valued at approximately $2,721,719.91. This represents a 1.01% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Anixa Biosciences Stock Performance

Shares of ANIX opened at $2.69 on Wednesday. Anixa Biosciences Inc has a 52 week low of $2.32 and a 52 week high of $5.46. The stock has a market capitalization of $93.50 million, a price-to-earnings ratio of -8.41 and a beta of 0.51. The stock has a fifty day moving average of $3.32 and a 200-day moving average of $2.98.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). As a group, equities analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Anixa Biosciences during the 2nd quarter worth approximately $559,000. GSA Capital Partners LLP acquired a new stake in Anixa Biosciences in the second quarter worth $329,000. Renaissance Technologies LLC grew its holdings in Anixa Biosciences by 13.6% in the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after purchasing an additional 7,300 shares during the period. Kestra Advisory Services LLC increased its stake in Anixa Biosciences by 96.2% in the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Anixa Biosciences in the second quarter valued at $133,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Finally, Weiss Ratings downgraded shares of Anixa Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.